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Background: Chronic obstructive pulmonary disease (COPD) is a complex inflammatory condition in which an
important extra-pulmonary manifestation is cardiovascular disease. We hypothesized that COPD patients would
have increased aortic inflammation and stiffness, as candidate mechanisms mediating increased cardiovascular risk,
compared to two negative control groups: healthy never-smokers and smokers without COPD. We also studied
patients with COPD due to alpha− 1 antitrypsin deficiency (α1ATD) as a comparator lung disease group.
Methods: Participants underwent 18F-Fluorodeoxyglucose (FDG) positron emission tomography imaging to quantify
aortic inflammation as the tissue-to-blood-ratio (TBR) of FDG uptake. Aortic stiffness was measured by carotid-femoral
aortic pulse wave velocity (aPWV).
Results: Eighty-five usual COPD (COPD due to smoking), 12 α1ATD-COPD patients and 12 each smokers and
never-smokers were studied. There was no difference in pack years smoked between COPD patients and smokers
(45 ± 25 vs 37 ± 19, p = 0.36), but α1ATD patients smoked significantly less (19 ± 11, p < 0.001 for both). By design,
spirometry measures were lower in COPD and α1ATD-COPD patients compared to smokers and never-smokers.
Aortic inflammation and stiffness were increased in COPD (TBR: 1.90 ± 0.38, aPWV: 9.9 ± 2.6 m/s) and α1ATD
patients (TBR: 1.94 ± 0.43, aPWV: 9.5 ± 1.8 m/s) compared with smokers (TBR: 1.74 ± 0.30, aPWV: 7.8 ± 1.8 m/s,
p < 0.05 all) and never-smokers (TBR: 1.71 ± 0.34, aPWV: 7.9 ± 1.7 m/s, p ≤ 0.05 all).
Conclusions: In this cross-sectional prospective study, novel findings were that both usual COPD and α1ATD-COPD
patients have increased aortic inflammation and stiffness compared to smoking and never-smoking controls, regardless
of smoking history. These findings suggest that the presence of COPD lung disease per se may be associated with
adverse aortic wall changes, and aortic inflammation and stiffening are potential mechanisms mediating increased
vascular risk observed in COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a
complex condition, associated with extra-pulmonary
manifestations that contribute to poor health and mor-
tality [1]. COPD patients have two-to-five fold increased
cardiovascular risk compared to the general population,
and cardiovascular disease (CVD) accounts for a third of
all deaths in people with COPD [2, 3]. The precise
mechanisms leading to increased cardiovascular risk in
COPD patients are unclear. Smoking is an obvious
shared risk factor, but several other mechanisms includ-
ing systemic inflammation (which is the elevated levels
of circulating inflammatory cells, cytokines or proteins,
measured from the systemic circulation), potentially of
pulmonary origin, and vascular inflammation and stiff-
ening, may also be involved.
Inflammation plays an important role in the pathogen-
esis of both COPD and CVD, and increased markers of
systemic inflammation, are associated with a poor progno-
sis in COPD [4, 5]. Local vascular inflammation measured
by 18F-Fluorodexoyglucose positron emission tomography
(FDG PET) imaging, is a promising vascular biomarker
[6, 7] that correlates with atheromatous plaque
macrophage content [8], and aortic inflammation
quantified by FDG PET, has been shown to independently
predict future cardiovascular events beyond the
Framingham Risk Score (FRS) [9]. Interestingly, there are
very few studies that have assessed vascular inflammation
assessed by FDG PET in COPD patients. A small pilot
study has previously reported increased aortic
inflammation assessed by FDG PET in seven COPD
patients compared to seven ex-smoker controls with nor-
mal spirometry. However, given that study groups were
poorly matched for smoking exposure [10], it is uncertain
whether observed differences were due to the presence of
COPD per se or tobacco consumption.
Aortic stiffness defined by the gold standard of (carotid-
femoral) aortic pulse wave velocity (aPWV) is also reported
to be increased in COPD patients [11]. A recent meta-
analysis indicates that aPWV predicts future cardiovascular
events and mortality independently of traditional cardiovas-
cular risk factors [12]. Increased aortic stiffness is itself associ-
ated with elevated systemic markers of inflammation in
diverse conditions [13, 14], which may help explain why
chronic inflammatory conditions such as rheumatoid arthritis
have increased cardiovascular risk [15]. However, interest-
ingly, we have recently shown in a large study of COPD
patients, that despite having elevated systemic inflammatory
markers, no independent relationship between aortic stiffness
measured by aPWV and systemic inflammatory markers was
observed [16]. Moreover, the relationship between anatomic-
ally localized vascular inflammation measured by FDG PET
and both vascular stiffening and systemic inflammation in
COPD patients, has not thus far been assessed.We hypothesized that ‘usual COPD’ (COPD due to
smoking) patients would have both increased aortic in-
flammation and aortic stiffness, independently of
cigarette smoking. We also sought to determine the
interaction of these vascular manifestations with lung
disease per se, by also studying patients with COPD due
to alpha-1 antitrypsin deficiency (α1ATD), as a positive
lung disease control group. Furthermore, we examined
the relationship between aortic inflammation measured
by FDG PET with aortic stiffness and calcification,
markers of systemic inflammation and measures of
COPD severity, to better understand mechanisms of vas-
cular risk in this complex condition.
Methods
Data presented in this manuscript includes subjects re-
cruited to the EVOLVE study (REC 13/EE/0165, UK CRN
ID 1513) and EVOLUTION trial (NCT01541852).
EVOLVE is a cross-sectional prospective FDG PET im-
aging study that was conducted in parallel to the EVOLU-
TION trial and included COPD patients with a plasma
fibrinogen ≤2.8 g/l, α1ATD-COPD (Pi Z phenotype)
patients, and smokers and never-smokers without COPD.
EVOLUTION is a phase 2a randomized placebo-
controlled trial of losmapimod in COPD patients with a
plasma fibrinogen level > 2.8 g/L. Further information
regarding the EVOLUTION trial has previously been pub-
lished [17, 18]. In this manuscript, we have used the base-
line data of these COPD patients recruited to the
EVOLUTION trial in addition to COPD patients from
EVOLVE to assess data from COPD patients with a range
of plasma fibrinogen values, (plasma fibrinogen is a sys-
temic inflammatory marker associated with increased car-
diovascular risk [19, 20]), without incurring additional
scans and associated ionizing radiation exposure. In
addition, we have been able to longitudinally assess vascu-
lar FDG PET over a 4-month time period in COPD
patients who received placebo as part of the trial.
Identical protocols were used for all subjects from
both studies, for all data assessments presented in this
manuscript, including scanning, hemodynamic measure-
ments, and laboratory tests for example. In addition, the
same equipment (e.g. scanners and machines), and study
personnel conducted both studies. Both studies recruited
subjects from two UK tertiary centers and received
favorable opinions from the Cambridge South Research
Ethics Committee. Written informed consent was
obtained from all participants and the studies were car-
ried out in accordance with institutional guidelines and
the Declaration of Helsinki.
Subject groups
There were four subject groups, which included 85
‘usual’ COPD patients (with ≥10 pack years smoked
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smokers and 12 never-smokers, both with normal pre-
dicted spirometry. Smokers without COPD, had greater
than a 10 pack year history, and smoked approximately
> = 10 cigarettes per day in the preceding 12 months of
study enrolment. Both COPD and α1ATD-COPD
patients had to be clinically stable, and free of exacerba-
tions in the preceding 4 weeks before enrolment in the
study. Moreover, any other known chronic inflammatory
conditions, a cardiovascular event in the preceding 6
months to study enrolment, and insulin dependent dia-
betes were the main exclusion criteria for all subject
groups. The usual COPD patient group comprised baseline
data (i.e prior to intervention of placebo or losmapimod)
of 73 COPD patients with a plasma fibrinogen > 2.8 g/l
enrolled in the EVOLUTION trial and 12 COPD patients
with a fibrinogen ≤2.8 g/l. Age and gender were matched
across the four groups as closely as possible to enable
cross-sectional analysis of the different subject groups.
Scan imaging and analysis
18F-Fluorodeoxyglucose positron emission tomography co-
registered with computed tomography (FDG PET/CT) im-
aging of the aorta and carotid arteries were performed. Full
imaging methods are explained in the Additional file 1. For
image analysis, Osirix open source DICOM software (v5.6,
Osirix Imaging Software, Geneva, Switzerland) was used.
The maximum standardized uptake value (SUVmax) of
FDG within each axial PET/CT fused image of artery, con-
taining wall and lumen, was divided by the average blood
FDG concentration in the superior vena cava or jugular
vein (for carotids) to yield an arterial maximum tissue-to-
blood (TBR) ratio, as a quantitative measure of arterial
tracer uptake, see Fig. 1. Average TBR for thoracic aorta,
abdominal aorta, and entire aorta, as well as average TBRFig. 1 Typical fused PET/CT image. a Fused FDG PET/CT axial image of the
by dividing FDG uptake in aorta (green circles) by uptake in the superior vefor the right and left carotid arteries combined, were calcu-
lated. Additional analysis examined the proportion of aortic
slices with a TBR > 2, which was used as a threshold to de-
fine highly inflamed areas of aorta [21]. All scans were ana-
lyzed by an experienced reader, anonymized to patient
identifiable information, subject group, and visit number.
Aortic calcification (defined by an attenuation threshold
≥130 Hounsfield units in 3 contiguous voxels as per the
Agatston method [22]) was analyzed for each cross sec-
tional CT scan slice of aorta [23]. The total score for the
aorta was obtained by adding scores from all cross-
sectional images. Emphysema severity, defined by the Perc
15 score (Hounsfield Units) which is a measure of lung
density [24], was also calculated from CT scan imaging.
Data from the placebo group of the EVOLUTION trial
enabled longitudinal analysis of the stability of aortic
inflammation in 34 COPD patients. Aortic TBR values
derived from baseline and repeat imaging at 4 months
were compared.
Hemodynamic assessments
aPWV was measured using a high fidelity microman-
ometer (SPC-301, Millar Instruments, Houston, Texas)
and Sphygmocor device (Sphygmocor, AtCor Medical,
Sydney, Australia), as previously described [25].
Blood biomarkers of inflammation
Blood samples were analyzed for high sensitivity CRP
(hsCRP), plasma fibrinogen (Klauss method), as well as
total white cell count (WCC), neutrophils and eosino-
phils, in NHS laboratories using validated assays.
Statistical analysis
Sample size was determined based on previous data
evaluating vascular inflammation in COPD patientsaorta and superior vena cava. b Tissue-to-blood ratio (TBR) calculated
na cava (small green circle)
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cludes the largest to date, prospective cohort of COPD
patients with vascular FDG PET imaging. Data were an-
alyzed using SPSS software (version 23). Mixed model
linear regression analyses were used to evaluate TBR
data with study site as a covariate. In addition, a logistic
regression model with a binary outcome response of
TBR > 2 or ≤ 2, with site also as a covariate, was also per-
formed. Mann-Whitney U test was used to compare
aortic calcification to never-smokers. Blood biomarker
data were log10 transformed prior to statistical analyses.
Pearsons two-tailed r test or Spearman’s rho were used
to evaluate correlations, and unpaired t-test and Chi-
square test were used to compare demographic data to
never-smokers. Data are expressed as mean ± standard
deviation (SD), median (interquartile range (IQR)) where
appropriate. Bar graphs (with error bars) represent mean
(95% confidence intervals (CI)) values. A p-value < 0.05
was deemed statistically significant for all analyses.Table 1 Demographic characteristics of subject groups
Variable COPD n = 85
Demographics
Age (years) 68 ± 8
Gender (% male) 67
BMI (kg/m2) 25.9 ± 3.9
Current smoker n (%) 11 (13)***
Pack years smoked 45 ± 25***
Statin therapy n (%) 26 (31)*
Lung function
FEV1 (L) 1.37 ± 0.6***
FEV1% predicted 51 ± 20***
GOLD stage II/III (%) 77
Perc 15 score (HU) − 890 ± 54***
Hemodynamic measurements
SBP (mmHg) 137 ± 18
DBP (mmHg) 79 ± 7
Heart rate (bpm) 71 ± 18
Aortic pulse wave velocity (m/s) 9.9 ± 2.6*
Laboratory data
Fibrinogen (g/L) 3.4 ± 0.7*
hsCRP (mg/L) 5.2 ± 7.0*
White cell count (×109/L) 6.54 ± 1.83
Neutrophils (×109/L) 4.43 ± 3.6
LDL Cholesterol (mmol/L) 2.9 ± 1.0
Total/HDL Cholesterol (mmol/L) 3.5 ± 1.3
Triglycerides (mmol/L) 1.4 ± 0.8
Mean ± SD presented. Data are presented compared to never-smokers. Unpaired t-t
smokers: ***p < 0.001, *p < 0.05 compared to never-smokers
BMI Body mass index, FEV1 Forced expiratory lung volume in 1 s, GOLD (Global Obs
diastolic blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein,Results
Eighty-five COPD patients, 12 α1ATD-COPD patients,
12 each healthy smokers and never-smokers were stud-
ied. The demographic data for each group are summa-
rized in Table 1. COPD patients were aged 68 ± 8 years;
never-smokers 69 ± 7 years and both smokers and
α1ATD patients were slightly younger at 62 ± 6 years
and 62 ± 8 years, respectively. There were a higher pro-
portion of women in the α1ATD and smokers groups,
although this did not reach statistical significance. There
was no difference in pack years smoked between COPD
patients and smokers (43 ± 21 versus 37 ± 19 pack years,
p = 0.36) but both groups smoked significantly more
than α1ATD patients (19 ± 11 pack years, p < 0.001 for
both). Sixty-eight (80%) of COPD patients and 10 (83%)
of α1ATD patients used a combined long acting beta
agonist/inhaled corticosteroid inhaler. Out of the whole
study population, 4 subjects; who were COPD patients,
had type 2 diabetes, which was controlled with oralα1ATD n = 12 Smokers n = 12 Never smokers n = 12
62 ± 8* 62 ± 6* 69 ± 7
73 58 83
25.0 ± 3.3 23.1 ± 2.3* 26.6 ± 2.6
2 (17)*** 12 (100)*** 0
19 ± 11*** 37 ± 19*** 0
0*** 0*** 2 (17)
1.47 ± 0.4*** 2.84 ± 0.6 2.88 ± 0.6
45 ± 16*** 95 ± 17 100 ± 15
83 – –
− 942 ± 18*** −818 ± 23 −806 ± 36
132 ± 11 134 ± 16 131 ± 8
84 ± 8 84 ± 7 79 ± 7
76 ± 10 67 ± 16 66 ± 10
9.5 ± 1.8* 7.8 ± 1.8 7.9 ± 1.7
3.1 ± 0.6 2.8 ± 0.6 2.7 ± 0.5
3.3 ± 2.3* 2.1 ± 1.4 1.2 ± 0.6
7.01 ± 2.72 7.28 ± 2.02 5.84 ± 1.31
4.68 ± 2.47 4.53 ± 1.45 3.63 ± 1.11
3.54 ± 0.4 3.1 ± 1.1 3.1 ± 1.1
3.5 ± 1.3 3.5 ± 1.6 3.4 ± 1.2
1.5 ± 1.0 1.2 ± 0.7 1.2 ± 0.5
est or Chi-square test used to determine differences compared to never-
tructive Lung Disease), HU Hounsfield Units, SBP systolic blood pressure, DBP
hsCRP (high sensitivity C-reactive protein)
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taking statins, whereas 26 COPD patients (31%) and 2
never-smokers (17%) were. There were no differences in
the lipid profile or pre-scan glucose levels between any
subject groups.
Vascular inflammation
Both COPD and α1ATD patients had increased inflamma-
tion in the thoracic, abdominal and entire aorta in compari-
son to healthy smokers (p < 0.001 for all) and never-smokers,
(p < 0.001 for all), Table 2 and Fig. 2. The greatest difference
in aortic inflammation for both COPD and α1ATD patients,
compared to never-smokers, was in the abdominal aorta,
with differences in TBR of + 15%, p < 0.001, and + 18% p < 0.
001, respectively. COPD and α1ATD patients also had a
greater proportion of highly inflamed (TBR> 2) aortic slices
(31 and 34% respectively), versus controls (smokers and
never-smokers data combined), who had only 9%, p < 0.001
for both. Interestingly, α1ATD patients were more inflamed
than COPD patients (p < 0.001), and there were no differ-
ences in TBR between COPD patients who were smokers
and ex-smokers in any aortic region. Furthermore, aortic in-
flammation was evaluated at baseline and at 4-months in
COPD patients who received placebo in the EVOLUTION
trial, and it did not change significantly (baseline TBR: 1.89 ±
0.28 versus 4 months TBR: 1.87 ± 0.27, p= 0.54).
In regard of aortic calcification, an inverse associ-
ation between aortic TBR and calcification was ob-
served (rho = − 0.28, p = 0.04), and COPD patients had
the most aortic calcification compared to never-
smokers who had the least, p = 0.02, Table 2. None-
theless, there were no significant differences in aortic
calcification between α1ATD patients, smokers and
never-smokers.
In the carotid artery, COPD patients had a higher TBR
(1.74 ± 0.22), than all other groups, p < 0.001, but there
were no statistically significant differences in carotid
TBR between α1ATD patients, smokers or never-
smokers.
There was no correlation between age, body mass index
(BMI), or pack years smoked with aortic TBR, but carotidTable 2 Image data
Image variable COPD n = 85 α
Thoracic TBR 1.90 ± 0.33*** 1
Abdominal TBR 1.89 ± 0.32*** 1
Entire Aorta TBR 1.90 ± 0.38*** 1
Carotid TBR 1.74 ± 0.22*** 1
Aortic calcification (Agatston Units) 2018 * (1089, 3581) 3
Aortic calcification (mm3) 2504* (1403, 4393) 1
Mean ± SD, median (IQR) presented. Data are presented compared to never-smoker
compared to never-smokers, Mann-Whitney U test to compare aortic calcification to
TBR tissue-to-blood ratioTBR did correlate with pack years (r = 0.34, p = 0.03).
There was an association between thoracic and ab-
dominal aortic TBR (r = 0.66, p < 0.001), but correla-
tions between carotid TBR with both thoracic and
abdominal TBR were non-significant (r = 0.11, p = 0.26
and r = 0.18, p = 0.05).
Aortic stiffness
aPWV was increased in COPD and α1ATD patients
compared to controls (both never-smokers and smokers)
, p ≤ 0.05 for all. After adjustment for mean arterial pres-
sure and heart rate, a difference of + 1.4 m/s in aPWV
(95% CI 8.83, 10.17), p = 0.01, between lung disease
patients (COPD and α1ATD patients data combined)
and controls (smokers and never-smokers data com-
bined) was observed. However, aPWV was similar be-
tween the two lung disease groups, and also between the
two control groups.
Aortic inflammation, stiffness and calcification
We observed no correlation between aortic inflamma-
tion and stiffness in any subject group or the whole co-
hort. However, given that aortic calcification was
positively correlated with aPWV (r = + 0.30, p = 0.001),
but inversely correlated with aortic TBR, analysis of only
subjects with no aortic calcification was performed. This
showed a modest positive but non-significant correl-
ation between aortic TBR and aPWV in the whole
cohort (n = 10 subjects, r = + 0.37, p = 0.28).
Vascular and systemic inflammation
There was a borderline significant positive correlation
between abdominal aortic TBR with both WCC and
neutrophils (r = + 0.18, p = 0.05 and r = + 0.17, p = 0.06)
in the whole cohort only. In α1ATD patients, a correl-
ation between fibrinogen and aortic TBR (r = + 0.71, p =
0.01) was observed, but not in COPD patients, or the
whole cohort. In the carotid artery, a modest correlation
with hsCRP was seen in COPD (r = + 0.23, p = 0.04),
α1ATD patients (r = + 0.67, p = 0.01), and the whole co-
hort (r = + 0.41, p = 0.02), and in COPD patients, also a1ATD n = 12 Smokers n = 12 Never smokers n = 12
.91 ± 0.40*** 1.74 ± 0.32 1.76 ± 0.31
.94 ± 0.44*** 1.67 ± 0.23 1.64 ± 0.24
.94 ± 0.43*** 1.74 ± 0.30 1.71 ± 0.34
.57 ± 0.46 1.61 ± 0.31 1.60 ± 0.30
99 (12, 1468) 807 (118, 3201) 274 (0,1314)
778 (147, 5683) 926 (153, 5976) 344 (0, 2456)
s. Mixed model linear regression analysis used to evaluate differences in TBR
never-smokers. ***p < 0.001,*p < 0.05 compared to never-smokers
Fig. 2 Mean tissue-to-blood ratio (TBR) in each of the aortic regions and carotid artery. a. Thoracic aorta, b. Abdominal aorta, c. Whole aorta,
d. Carotid artery. Bars represent mean values and error bars represent 95% CI. Overall significance for each model was p < 0.001. Pairwise
comparisons are illustrated by *p < 0.001 compared to never smokers, † p < 0.001 compared to smokers, ‡p < 0.01 compared to α1ATD patients
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with carotid TBR (r = + 0.33, p = 0.03 and r = + 0.26, p =
0.03, respectively) was observed. In COPD patients, we
also examined if there was a correlation between eosino-
phil counts with aortic or carotid inflammation, and no
significant correlations were found.
Vascular inflammation and COPD severity
In COPD patients, inverse correlations between abdominal
aortic TBR with FEV1% predicted, (r = − 0.19, p = 0.07),
FVC % predicted (r = − 0.29, p = 0.007) and the Perc 15
score of emphysema severity (r = − 0.25, p = 0.01) were
observed, but there were no correlations between
measures of COPD severity with thoracic aortic or
carotid artery TBR.
Discussion
The novel findings of this prospective study are that
increased aortic inflammation and aortic stiffness are
found in both ‘usual’ COPD and α1ATD-related
COPD patients, compared to control smokers and
never-smokers. In contrast, there was no difference in
these surrogate markers of CVD between smokers
and never-smokers. Moreover, COPD patients had in-
creased carotid artery inflammation compared to all
other subject groups and increased aortic calcification
compared to never-smokers. We also demonstrated
that aortic inflammation in COPD patients is a stable
finding, over a 4-month period. Additional novelfindings include the lack of a cross-sectional relation-
ship between aortic inflammation and aortic stiffness
in COPD patients. Taken together, these data suggest
that cardiovascular risk in COPD patients plausibly
relates to vascular inflammation and stiffening, these
are distinct mechanistic entities in cross-sectional
analysis at least; and these findings cannot be simply
attributed to smoking.
For the first time, we have demonstrated that both
COPD and α1ATD-related COPD patients have in-
creased aortic inflammation compared to smokers and
never-smokers without COPD. The findings of + 15%
and + 18% higher aortic TBR seen in COPD and α1ATD
patients compared to controls, is a clinically important
difference, that may be a target for anti-inflammatory
therapy, since intervention studies report a 6–15% re-
duction in TBR with anti-inflammatory treatments such
as anti-tumor necrosis-α therapy, or high-dose statins
(80 mg atorvastatin) [21, 26]. We also found that both
COPD and α1ATD-related COPD patients had higher
aortic TBR values than we previously reported in athero-
sclerosis subjects, but lower than in rheumatoid arthritis
(RA), which is a condition with marked inflammation
[21]. For the first time, we have also shown that COPD
patients demonstrated increased carotid inflammation.
These are clinically important findings since in athero-
sclerosis, FDG uptake is consistent with the increased
metabolic activity of macrophages in inflamed plaque [6]
which have a greater propensity to rupture and cause
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[6], and retrospective studies in cancer surveillance
cohorts, have demonstrated a positive, independent rela-
tionship between aortic inflammation and future cardio-
vascular events [7, 9]. Indeed, aortic TBR strongly
predicted cardiovascular events independently of trad-
itional risk factors including coronary calcium score
(hazard ratio: 4.13; 95% CI: 1.59 to 10.76; p = 0.004),
improved net reclassification of risk when incorporated
into the Framingham risk model (27.48% (95% CI: 16.27
to 39.93) for 10% risk) and also was inversely associated
with the timing of cardiovascular events (β − 0.0096; p <
0.0001) in analysis of 513 consecutive individuals who
underwent FDG PET imaging with no prior history of
CVD [7, 9]. Furthermore, carotid TBR correlated with
atheromatous plaque macrophage content in endarterec-
tomy specimens of patients with cerebrovascular disease
[8], related to clinically significant culprit lesions follow-
ing a recent transient ischaemic attack (TIA), and culprit
carotid non-stenotic lesions identified on magnetic reso-
lution imaging as compatible with symptomatic vessel
territories [27, 28]. Carotid inflammation may therefore
be an important factor in the increased risk of stroke ob-
served in COPD patients [29] and is an area that re-
quires further research.
Interestingly, we found no difference in vascular
inflammation levels measured by FDG PET between
control smokers and never-smokers, which is consistent
with previous data [30]. A potential explanation for this
finding is that FDG uptake and vascular calcification are
inversely related [31], and more aortic calcification
observed in smokers (although not statistically signifi-
cant), is a possible confounding factor. A further option,
is that genetic predisposition to the noxious effects of
smoke in the lungs [32] and vasculature, may explain
differences between patients with lung disease and
healthy smokers, especially as α1ATD patients had the
highest levels of aortic inflammation, despite smoking
significantly less than control smokers and COPD
patients. Regarding, the lack of difference in aortic stiff-
ness between smokers and never-smokers, large
hemodynamic studies such as Framingham and the An-
glo Cardiff Collaborative Trial also found either no (or a
modest) influence of smoking on aortic stiffness [33, 34].
Further novel findings from the current study are that
regional differences in vascular bed inflammation may
have different etiological factors, particularly since
α1ATD patients had increased aortic inflammation spe-
cifically, but low levels of carotid TBR. As FDG uptake
in vascular imaging can be due to atherosclerotic plaque,
or arterial wall inflammation, an important hypothesis
from our data is that aortic inflammation and stiffness in
α1ATD may be due to non-atherosclerotic vascular
changes, since carotid artery inflammation (which in aprevious study histologically corroborated with ather-
omatous plaque activity [8]) was low in these patients
and in contrast to usual COPD patients, α1ATD-COPD
patients did not have significant aortic calcification.
Interestingly, α1ATD patients demonstrated the highest
levels of inflammation in the abdominal aorta, and a
relationship between measures of COPD severity and
abdominal aortic TBR was observed. The mechanical
effects of hyperinflation [35] which is associated with
haemodynamic effects [36], intra-thoracic pressure
swings associated with obstructive lung disease [37], and
coughing and snoring [38] are all potential explanations.
It is also possible that we have overlooked an unknown
shared pathological mechanism, between aortic wall dis-
orders and COPD and α1ATD-related COPD. Mediators
of inflammatory extracellular matrix degradation, elastin
loss and chronic inflammation are recognized in the
pathogenesis of emphysema and COPD [39], as well as
aortic dilatation, stiffening and aneurysm formation.
Indeed, we found that both COPD and α1ATD patients
compared to controls had increased aortic stiffness
which is consistent with previous data [11, 40]. This
is clinically relevant given the independent association
between aPWV and cardiovascular events and mortal-
ity [12].
Increased aortic inflammation and stiffness observed
in α1ATD patients with COPD, suggests that COPD per
se may be associated with these adverse aortic changes
and that these patients are also at increased cardiovascu-
lar risk. This is interesting since previous data regarding
cardiovascular risk in α1ATD, unlike in usual COPD
studies, are inconsistent. In the Copenhagen City Heart
Study, α1ATD was associated with reduced blood pres-
sure in ischaemic heart disease patients, but only 6 sub-
jects had the PiZ phenotype (which was a tiny fraction
of the population cohort, < 0.05%), and their lung func-
tion was not reported [41]. In contrast, it is reported
that low levels of the α1AT protein are associated with
atherosclerosis progression, defined by change in coron-
ary artery luminal diameter, measured by quantitative
angiography, in subjects with established vascular dis-
ease, who had undergone previous coronary artery
bypass surgery [42].
A further new finding of the current study is that we
observed no significant relationship between aortic
inflammation and stiffness in any subject group. In con-
trast, we previously observed a correlation between the
reduction in aortic inflammation and reduction in aortic
stiffness following anti-TNF therapy in rheumatoid arth-
ritis patients [21, 43]. Our data suggests that aortic
inflammation and stiffness are either two distinct mech-
anisms of increased vascular risk in COPD, or there is a
temporal link between them, which is not seen in this
cross-sectional analysis. Aortic inflammation does
Fisk et al. Respiratory Research  (2018) 19:100 Page 8 of 10precede calcium deposition in the same anatomical loca-
tion of the aortic wall [44], and aortic calcification is
associated with aortic stiffness in systolic hypertension
subjects and in COPD patients, which is consistent with
our data [45, 46]. Interestingly, we found that usual
COPD patients had significantly more aortic calcification
compared to age matched never-smokers, further sup-
porting the notion of premature vascular ageing, and in-
creased cardiovascular risk associated with COPD [47].
Furthermore, experimental data in pre-clinical mouse
models, showed that pro-inflammatory pathways regu-
late elastinolysis and can trigger vascular osteogenesis
[48]. Given that tracer uptake is diminished in regions of
calcification [31], the finding that COPD patients had
increased aortic FDG uptake, and aortic calcification
compared to controls does suggest that aortic inflamma-
tion levels would be even higher in COPD patients,
before calcification was established. We speculate there-
fore, that aortic elastin degradation due to inflammatory
processes may be the process linking aortic inflamma-
tion, stiffening, and calcification in COPD.
The mechanistic importance of systemic inflammation
in vascular inflammation in COPD is uncertain. Our
finding of a correlation between hsCRP and carotid TBR
in all subject groups is consistent with published data
[49]. However, in cross-sectional analysis at least, it
seems that systemic inflammatory markers are poor sur-
rogate markers of aortic inflammation in COPD, and of
note, other studies have shown a lack of association be-
tween systemic inflammation and aortic stiffness in
COPD [16].
The strengths of this study are that we have used a
reliable, state of the art imaging technique to examine
in-vivo anatomically-localized vascular inflammation
[6, 50], and enabled assessment of its relationship
with vascular stiffness and systemic inflammation in
the largest prospective cohort of COPD patients with
PET vascular imaging. The main limitation is its
cross-sectional nature, which does not permit any as-
sessment of causality. A further potential limitation is
that we selected α1ATD patients as a positive, COPD
lung disease control group, and although these pa-
tients had significantly lower smoking history, it was
hard to find α1ATD patients with COPD who were
never-smokers. Similarly, it was difficult to exactly
match the four subject groups for age and gender,
and although there were no statistically significant
differences across the groups, α1ATD patients and
smokers tended to be younger and have a higher pro-
portion of women than the usual COPD and never-
smoker groups. Furthermore, the influence on our re-
sults of respiratory medication use such as inhaled
corticosteroids, as well as the fact a sizeable propor-
tion of COPD patients were already on statins needsconsideration. However, one would expect these med-
ications to reduce vascular inflammation and stiffness,
therefore diminishing the observed difference between
COPD patients and controls [51]. Another point of
consideration is that this was a mechanistic observa-
tional study involving ionizing radiation. Therefore we
used the smallest number of controls possible to test our
hypothesis. However, our sample size is in keeping with
other FDG PET studies of this nature [10, 28]. Finally, we
used normalized FDG uptake, which is a measure of cellu-
lar glycolytic activity, as a surrogate measure of arterial
wall inflammation [6]. However, FDG is a non-specific
tracer, taken up by all metabolically active cells, and there-
fore does not dissect the different cellular profiles involved
in vascular inflammation in usual COPD and α1ATD
patients, whether there are differences between these
groups, or compared to atherosclerosis subjects. More tar-
geted tracers, for example in atherosclerosis imaging,
11C-PK11195 and 68Ga- DOTATATE have been used to
evaluate macrophage activity [7], may be of value for
evaluating specific interventions in the future.
Conclusions
COPD patients have increased aortic inflammation and
stiffness, irrespective of tobacco consumption, which are
plausible mechanisms mediating increased cardiovascu-
lar risk, associated with COPD. COPD patients also
demonstrated increased carotid inflammation and aortic
calcification, which further demonstrates the adverse
vascular characteristics of these patients, and the need
for action to improve understanding of cardiovascular
risk in COPD to positively influence outcomes. More-
over, our data raises interesting questions regarding the
etiology of vascular inflammation affecting different ar-
terial territories in COPD, which is a topic that should
be addressed in further studies. Additionally, trials with
these non-invasive vascular markers, and therapeutic
intervention to attenuate them, with the aim to reduce
cardiovascular risk, are needed.
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